The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
Open accessAbstract
Mutations affecting spliceosomal proteins are the most common mutations in patients with myelodysplastic syndromes (MDS), but their role in MDS pathogenesis has not been delineated. Here we report that mutations affecting the splicing factor SRSF2 directly impair hematopoietic differentiation in vivo, which is not due to SRSF2 loss of function. By contrast, SRSF2 mutations alter SRSF2's normal sequence-specific RNA binding activity, thereby altering the recognition of specific exonic splicing enhancer motifs to drive recurrent mis-splicing of key hematopoietic regulators. This includes SRSF2 mutation-dependent splicing of EZH2, which triggers nonsense-mediated decay, which, in turn, results in impaired hematopoietic differentiation. These data provide a mechanistic link between a mutant spliceosomal protein, alterations in the splicing of key regulators, and impaired hematopoiesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSCs from mice mutant for these genes, Sf3b1 56, Srsf2 57, and U2af1 58, have a competitive disadvantage in vivo, unlike the clonal expansion observed in humans with these mutations.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes
Siepel, A., Bejerano, G., Pedersen, J. S., Hinrichs, A. S., Hou, M., Rosenbloom, K., Clawson, H., Spieth, J., Hillier, L. W., Richards, S., et al. (2005) · Genome Research · doi:10.1101/gr.3715005 · Cited by 3,971 · cited 2×
“(B) IntegrativeGenomics Viewer (IGV)/Sashimi plot illustrating theEZH2 cassette e patient numbers listed in the Sashimi plot correspond to the numbers in Table S1 as estimated by phastCons (Siepel et al., 2005), across 30 vertebrate species is (C) Bar plot describing the percentage of EZH2 transcripts harboring a spec…”
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Inducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. (2014) · Leukemia · doi:10.1038/leu.2013.336 · Cited by 1,532
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Self-citationSomatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Wang, L., Lawrence, M. S., Wan, Y., Stojanov, P., Sougnez, C. L., Stevenson, K. E., Werner, L. L., Sivachenko, A., DeLuca, D. S., Zhang, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109016 · Cited by 1,103
Quesada, V., Conde, L., Villamor, N., Ordóñez, G. R., Jares, P., Bassaganyas, L., Ramsay, A. J., Beà, S., Pinyol, M., Martínez‐Trillos, A., et al. (2011) · Nature Genetics · doi:10.1038/ng.1032 · Cited by 1,022
Cited by
Sorted by citations
U1 snRNP regulates cancer cell migration and invasion in vitro
Oh, J.-M., Venters, C. C., Di, C., Pinto, A. M., Wan, L., Younis, I., Cai, Z., Arai, C., So, B. R., Duan, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13993-7 · Cited by 7,157
Scotti, M. M., & Swanson, M. S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.3 · Cited by 1,163
Clonal hematopoiesis in human aging and disease
Jaiswal, S., & Ebert, B. L. (2019) · Science · doi:10.1126/science.aan4673 · Cited by 1,156
“HSCs from mice mutant for these genes, Sf3b1 (57), Srsf2 (58), and U2af1 (59), have a competitive disadvantage in vivo, unlike the clonal expansion observed in humans with these mutations.”
Goodall, G. J., & Wickramasinghe, V. O. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00306-0 · Cited by 1,090
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
Robertson, A. G., Shih, J., Yau, C. S. F., Gibb, E. A., Oba, J., Mungall, K. L., Hess, J. M., Uzunangelov, V., Walter, V., Danilova, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.003 · Cited by 908
Self-citationRoles and mechanisms of alternative splicing in cancer — implications for care
Bonnal, S., López‐Oreja, I., & Valcárcel, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0350-x · Cited by 760
RNA splicing factors as oncoproteins and tumour suppressors
Dvinge, H., Kim, E. H., Abdel-Wahab, O. I., & Bradley, R. K. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.51 · Cited by 706
Self-citationThe genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Sperling, A. S., Gibson, C. J., & Ebert, B. L. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.112 · Cited by 706
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
Vainchenker, W., & Královics, R. (2016) · Blood · doi:10.1182/blood-2016-10-695940 · Cited by 716
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
Self-citationTherapeutic targeting of splicing in cancer
Lee, S. C.-W., & Abdel-Wahab, O. I. (2016) · Nature Medicine · doi:10.1038/nm.4165 · Cited by 573
Self-citationSeiler, M., Yoshimi, A., Darman, R. B., Chan, B., Keaney, G. F., Thomas, M., Agrawal, A. A., Caleb, B. L., Csibi, A., Sean, E. E., et al. (2018) · Nature Medicine · doi:10.1038/nm.4493 · Cited by 529
Self-citationCazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 508
Clinical significance of somatic mutation in unexplained blood cytopenia
Malcovati, L., Gallì, A., Travaglino, E., Ambaglio, I., Rizzo, E., Molteni, E., Elena, C., Ferretti, V. V., Catricalà, S., Bono, E. B., et al. (2017) · Blood · doi:10.1182/blood-2017-01-763425 · Cited by 482
Darman, R. B., Seiler, M., Agrawal, A. A., Lim, K., Peng, S., Aird, D. R., Bailey, S., Bhavsar, E. B., Chan, B., Colla, S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.053 · Cited by 472
Self-citationMolecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
Grimwade, D. J., Ivey, A., & Huntly, B. J. P. (2015) · Blood · doi:10.1182/blood-2015-07-604496 · Cited by 475
Seiler, M., Peng, S., Agrawal, A. A., Palacino, J. J., Teng, T., Zhu, P., Smith, P. G., Johnson, R., Demchok, J. A., Felau, I., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.088 · Cited by 445
Self-citationUrbanski, L. M., Leclair, N. K., & Anczuków, O. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1476 · Cited by 393
Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease
Jaiswal, S., & Libby, P. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0247-5 · Cited by 386
Obeng, E. A., Chappell, R. J., Seiler, M., Chen, M. C., Campagna, D. R., Schmidt, P. J., Schneider, R. K., Lord, A. M., Wang, L., Gambe, R. G., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.006 · Cited by 380
Self-citationOgawa, S. (2019) · Blood · doi:10.1182/blood-2018-10-844621 · Cited by 382
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
Basiorka, A. A., McGraw, K. L., Eksioglu, E. A., Chen, X., Johnson, J., Zhang, L., Zhang, Q., Irvine, B. A., Cluzeau, T., Sallman, D. A., et al. (2016) · Blood · doi:10.1182/blood-2016-07-730556 · Cited by 367
Epidrugs: targeting epigenetic marks in cancer treatment
Furtado, C. L. M., Luciano, M. C. D. S., Santos, R. D. S., Furtado, G. P., de Moraes, M. O., & Pessoa, C. (2019) · Epigenetics · doi:10.1080/15592294.2019.1640546 · Cited by 361
Lee, S. C.-W., Dvinge, H., Kim, E. H., Cho, H., Micol, J., Chung, Y. R., Durham, B. H., Yoshimi, A., Kim, Y. J., Thomas, M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4097 · Cited by 359
Self-citationWidespread intron retention diversifies most cancer transcriptomes
Dvinge, H., & Bradley, R. K. (2015) · Genome Medicine · doi:10.1186/s13073-015-0168-9 · Cited by 372
Self-citationThe role of alternative splicing in cancer: From oncogenesis to drug resistance
Sciarrillo, R., Wojtuszkiewicz, A., Assaraf, Y. G., Jansen, G., Kaspers, G. J. L., Giovannetti, E., & Cloos, J. J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100728 · Cited by 317
Splicing-factor alterations in cancers
Anczuków, O., & Krainer, A. R. (2016) · RNA · doi:10.1261/rna.057919.116 · Cited by 304
Aberrant RNA Splicing in Cancer
Escobar‐Hoyos, L. F., Knorr, K. L. B., & Abdel-Wahab, O. I. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050407 · Cited by 303
Self-citationChen, L., Chen, J., Huang, Y.-J., Gu, Y., Qiu, J., Qian, H., Shao, C., Zhang, X., Hu, J., Li, H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2017.12.029 · Cited by 304
Self-citationTherapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation
Fong, J. Y., Pignata, L., Goy, P.-A. V., Kawabata, K. C., Lee, S. C.-W., Koh, C. M., Musiani, D., Massignani, E., Kotini, A. G., Penson, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.003 · Cited by 294
Self-citationSebestyén, E., Singh, B., Miñana, B., Pagès, A., Mateo, F., Pujana, M. A., Valcárcel, J., & Eyras, E. (2016) · Genome Research · doi:10.1101/gr.199935.115 · Cited by 276
Smith, M. A., Choudhary, G. S., Pellagatti, A., Choi, K., Bolanos, L. C., Bhagat, T. D., Gordon-Mitchell, S., Ahrens, D. V., Pradhan, K., Steeples, V., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0314-5 · Cited by 253
Pellagatti, A., Armstrong, R. N., Steeples, V., Sharma, E., Repapi, E., Singh, S., Sanchi, A., Radujkovic, A., Horn, P., Dolatshad, H., et al. (2018) · Blood · doi:10.1182/blood-2018-04-843771 · Cited by 248
Wang, E., & Aifantis, I. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.04.011 · Cited by 246
Self-citationChromatin-associated RNAs as facilitators of functional genomic interactions
Li, X., & Fu, X. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0135-1 · Cited by 236
Spliceosomal disruption of the non-canonical BAF complex in cancer
Inoue, D., Chew, G.-L., Liu, B., Michel, B. C., Pangallo, J., D’Avino, A. R., Hitchman, T. D., North, K., Lee, S. C.-W., Bitner, L. E., et al. (2019) · Nature · doi:10.1038/s41586-019-1646-9 · Cited by 233
Self-citationPRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes
Hamard, P.-J., Santiago, G. E., Liu, F., Karl, D. L., Martínez, C., Man, N., Mookhtiar, A. K., Duffort, S., Greenblatt, S. M., Verdún, R. E., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.002 · Cited by 232
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer
Bowling, E. A., Wang, J. H., Gong, F., Wu, W., Neill, N. J., Kim, I. S., Tyagi, S., Orellana, M. C., Kurley, S. J., Domínguez-Vidaña, R., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.031 · Cited by 227
Self-citationCoordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis
Yoshimi, A., Lin, K., Wiseman, D. H., Rahman, M. A., Pastore, A., Wang, B., Lee, S. C.-W., Micol, J., Zhang, X. J., de Botton, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1618-0 · Cited by 221
Self-citationThe Cancer Spliceome: Reprograming of Alternative Splicing in Cancer
Marabti, E. E., & Younis, I. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00080 · Cited by 224
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations
Lee, S. C.-W., North, K., Kim, E., Jang, E., Obeng, E., Lu, S. X., Liu, B., Inoue, D., Yoshimi, A., Ki, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.003 · Cited by 219
Self-citationRNA Splicing and Disease: Animal Models to Therapies
Montes, M., Sanford, B. L., Comiskey, D. F., & Chandler, D. S. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.10.002 · Cited by 225
Defective control of pre–messenger RNA splicing in human disease
Chabot, B., & Shkreta, L. (2016) · The Journal of Cell Biology · doi:10.1083/jcb.201510032 · Cited by 220
Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities
Zhang, J., Lieu, Y. K., Ali, A. M., Penson, A., Reggio, K. S., Rabadán, R., Raza, A., Mukherjee, S., & Manley, J. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514105112 · Cited by 223
Wang, L., Brooks, A. N., Fan, J., Wan, Y., Gambe, R. G., Li, S., Hergert, S., Yin, S., Freeman, S. S., Levin, J. Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.005 · Cited by 213
Self-citationCaye‐Eude, A., Strullu, M., Guidez, F., Cassinat, B., Gazal, S., Fenneteau, O., Lainey, É., Nouri, K., Nakhaei‐Rad, S., Dvorský, R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3420 · Cited by 197
Aberrant RNA Splicing in Cancer and Drug Resistance
Wang, B., & Lee, N. (2018) · Cancers · doi:10.3390/cancers10110458 · Cited by 183
Noncoding RNAs regulate alternative splicing in Cancer
Liu, Y., Liu, X., Lin, C., Jia, X., Zhu, H., Song, J. H., & Zhang, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01798-2 · Cited by 187
SRSF2 Regulates Alternative Splicing to Drive Hepatocellular Carcinoma Development
Luo, C., Cheng, Y., Liu, Y., Chen, L., Liu, L., Wei, N., Xie, Z., Wu, W., & Feng, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1919 · Cited by 174
Shiozawa, Y., Malcovati, L., Gallì, A., Sato‐Otsubo, A., Kataoka, K., Sato, Y., Watatani, Y., Suzuki, H., Yoshizato, T., Yoshida, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06063-x · Cited by 179
Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation
Gu, Z., Liu, Y., Cai, F., Patrick, M., Zmajkovic, J., Cao, H., Zhang, Y., Tasdogan, A., Chen, M., Qi, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0152 · Cited by 173
Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma
Suzuki, H., Kumar, S. A., Shuai, S., Díaz‐Navarro, A., Gutiérrez‐Fernández, A., Antonellis, P. D., Cavalli, F. M. G., Juraschka, K., Farooq, H., Shibahara, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1650-0 · Cited by 171
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome
Kennedy, J. A., & Ebert, B. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0806 · Cited by 175
Targeting transcription cycles in cancer
Vervoort, S. J., Devlin, J. R., Kwiatkowski, N. P., Teng, M., Gray, N. S., & Johnstone, R. W. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00411-8 · Cited by 170
Dysregulation and therapeutic targeting of RNA splicing in cancer
Stanley, R. F., & Abdel-Wahab, O. I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00384-z · Cited by 172
Self-citationAltered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer
Escobar‐Hoyos, L. F., Penson, A., Kannan, R., Cho, H., Pan, C., Singh, R. K., Apken, L. H., Hobbs, G. A., Luo, R., Lecomte, N., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.010 · Cited by 161
Self-citationNguyen, H. D., Leong, W. Y., Li, W., Reddy, P. N. G., Sullivan, J. D., Walter, M. J., Zou, L., & Graubert, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3970 · Cited by 169
Myeloproliferative neoplasms: from origins to outcomes
Nangalia, J., & Green, A. R. (2017) · Blood · doi:10.1182/blood-2017-06-782037 · Cited by 167
Leclair, N. K., Brugiolo, M., Urbanski, L. M., Lawson, S. C., Thakar, K., Yurieva, M., George, J., Hinson, J. T., Cheng, A. W., Graveley, B. R., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.019 · Cited by 150
Daguenet, É., Dujardin, G., & Valcárcel, J. (2015) · EMBO Reports · doi:10.15252/embr.201541116 · Cited by 159
Nonsense-mediated RNA decay: an emerging modulator of malignancy
Tan, K., Stupack, D. G., & Wilkinson, M. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00481-2 · Cited by 154
Chyla, B., Daver, N. G., Doyle, K. J., McKeegan, E. M., Huang, X., Ruvolo, V. R., Wang, Z., Chen, K., Souers, A. J., Leverson, J. D., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25146 · Cited by 148
Altered RNA Processing in Cancer Pathogenesis and Therapy
Obeng, E. A., Stewart, C., & Abdel-Wahab, O. I. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0399 · Cited by 145
Self-citationU2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3′ End Formation
Park, S. M., Ou, J., Chamberlain, L., Simone, T. M., Yang, H., Virbasius, C.-M. A., Ali, A. M., Zhu, L. J., Mukherjee, S., Raza, A., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.04.011 · Cited by 135
Splicing factor gene mutations in hematologic malignancies
Sáez, B., Walter, M. J., & Graubert, T. A. (2016) · Blood · doi:10.1182/blood-2016-10-692400 · Cited by 134
Emerging roles of spliceosome in cancer and immunity
Yang, H., Beutler, B., & Zhang, D. (2021) · Protein & Cell · doi:10.1007/s13238-021-00856-5 · Cited by 135
Mossner, M., Jann, J.-C., Wittig, J., Nolte, F., Fey, S., Nowak, V., Obländer, J., Pressler, J., Palme, I., Xanthopoulos, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679167 · Cited by 135
Mupo, A., Seiler, M., Sathiaseelan, V., Pance, A., Yang, Y., Agrawal, A. A., Iorio, F., Bautista, R., Pacharne, S., Tzelepis, K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.251 · Cited by 128
Self-citationSajini, A. A., Choudhury, N. R., Wagner, R. E., Bornelöv, S., Selmi, T., Spanos, C., Dietmann, S., Rappsilber, J., Michlewski, G., & Frye, M. (2019) · Nature Communications · doi:10.1038/s41467-019-10020-7 · Cited by 122
Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1
Zhang, J., Ali, A. M., Lieu, Y. K., Liu, Z., Gao, J., Rabadán, R., Raza, A., Mukherjee, S., & Manley, J. L. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.017 · Cited by 127
Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome
Shirai, C. L., White, B. S., Tripathi, M., TAPIA-CONYER, R. C., Ley, J. N., Ndonwi, M., Kim, S. P., Shao, J., Carver, A., Sáez, B., et al. (2017) · Nature Communications · doi:10.1038/ncomms14060 · Cited by 122
SnapShot: Splicing Alterations in Cancer
Rahman, M. A., Krainer, A. R., & Abdel-Wahab, O. I. (2020) · Cell · doi:10.1016/j.cell.2019.12.011 · Cited by 116
Self-citationJan, M., Ebert, B. L., & Jaiswal, S. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.10.002 · Cited by 119
How I treat chronic myelomonocytic leukemia
Solary, É., & Itzykson, R. (2017) · Blood · doi:10.1182/blood-2017-04-736421 · Cited by 112
Inoue, D., Bradley, R. K., & Abdel-Wahab, O. I. (2016) · Genes & Development · doi:10.1101/gad.278424.116 · Cited by 112
Self-citationFinci, L. I., Zhang, X., Huang, X., Zhou, Q., Tsai, J., Teng, T., Agrawal, A. A., Chan, B., Irwin, S., Karr, C. D., et al. (2018) · Genes & Development · doi:10.1101/gad.311043.117 · Cited by 108
Self-citationMinor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition
Inoue, D., Polaski, J. T., Taylor, J., Castel, P., Chen, S., Kobayashi, S. S., Hogg, S. J., Hayashi, Y., Pineda, J. M. B., Marabti, E. E., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00828-9 · Cited by 107
Self-citationMolecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms
Grinfeld, J., Nangalia, J., & Green, A. R. (2016) · Haematologica · doi:10.3324/haematol.2014.113845 · Cited by 108
Splicing factor mutations in hematologic malignancies
Chen, S., Benbarche, S., & Abdel-Wahab, O. I. (2021) · Blood · doi:10.1182/blood.2019004260 · Cited by 109
Self-citationQiu, P., Zhou, Y., Oyang, L., Wu, N., Tang, Y., Su, M., Luo, X., Wang, Y., Sheng, X., Ma, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.11.010 · Cited by 109
Komeno, Y., Huang, Y.-J., Qiu, J., Lin, L., Xu, Y., Zhou, Y., Chen, L., Monterroza, D. D., Li, H., DeKelver, R. C., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00202-15 · Cited by 104
Spliceosomopathies: Diseases and mechanisms
Griffin, C., & Saint‐Jeannet, J. (2020) · Developmental Dynamics · doi:10.1002/dvdy.214 · Cited by 96
Yoshimi, A., Balasis, M. E., Vedder, A., Feldman, K., Ma, Y., Zhang, H., Lee, S. C.-W., Letson, C. T., Niyongere, S., Lu, S. X., et al. (2017) · Blood · doi:10.1182/blood-2017-01-763219 · Cited by 101
Self-citationDifferential Functions of Splicing Factors in Mammary Transformation and Breast Cancer Metastasis
Park, S., Brugiolo, M., Akerman, M., Das, S., Urbanski, L. M., Geier, A., Kesarwani, A. K., Fan, M. Y., Leclair, N. K., Lin, K., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.110 · Cited by 97
Liang, Y., Tebaldi, T., Rejeski, K., Joshi, P. M., Stefani, G., Taylor, A., Song, Y., Vasic, R., Maziarz, J. D., Balasubramanian, K., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0152-7 · Cited by 98
Self-citationThe U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes
Yip, B. H., Steeples, V., Repapi, E., Armstrong, R. N., Llorian, M., Roy, S., Shaw, J. M., Dolatshad, H., Taylor, S., Verma, A. K., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91363 · Cited by 99
Wang, C., Yan, Y., Gao, S., Chen, J., Yu, J., Zhang, H., Li, M., Zhan, X., & Li, W. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.12.013 · Cited by 95
Clonal hematopoiesis and associated diseases: A review of recent findings
Asada, S., & Kitamura, T. (2021) · Cancer Science · doi:10.1111/cas.15094 · Cited by 104
Emerging concepts of epigenetic dysregulation in hematological malignancies
Ntziachristos, P., Abdel-Wahab, O. I., & Aifantis, I. (2016) · Nature Immunology · doi:10.1038/ni.3517 · Cited by 99
Self-citationWang, H., Fang, L., Jiang, J., Kuang, Y., Wang, B., Shang, X., Han, P., Li, Y., Liu, M., Zhang, Z., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1148-y · Cited by 92
Self-citationNonsense-mediated RNA decay and its bipolar function in cancer
Nogueira, G., Fernandes, R. O., García-Moreno, J. F., & Romão, L. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01364-0 · Cited by 93
Togami, K., Chung, S. S., Madan, V., Booth, C. A. G., Kenyon, C. M., Cabal‐Hierro, L., Taylor, J., Kim, S. S., Griffin, G. K., Ghandi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1513 · Cited by 90
Self-citationLi, H., Hu, F., Gale, R. P., Sekeres, M. A., & Liang, Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00402-5 · Cited by 96
Self-citationThe expansion of targetable biomarkers for CAR T cell therapy
Townsend, M. H., Shrestha, G., Robison, R. A., & O'Neill, K. L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0817-0 · Cited by 90
The role of alternative splicing in cancer
Singh, B., & Eyras, E. (2016) · Transcription · doi:10.1080/21541264.2016.1268245 · Cited by 85
Recurrent SRSF2 mutations in MDS affect both splicing and NMDPreprint
Rahman, M. A., Lin, K., Bradley, R. K., Abdel-Wahab, O. I., & Krainer, A. R. (2020) · Genes & Development · doi:10.1101/gad.332270.119 · Cited by 85
Self-citationCherry, S. R., & Lynch, K. W. (2020) · Genes & Development · doi:10.1101/gad.338962.120 · Cited by 90
Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies
Taylor, J., & Lee, S. C.-W. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22784 · Cited by 88
Self-citationThe role of RNA alternative splicing in regulating cancer metabolism
Kozlovski, I., Siegfried, Z., Amar-Schwartz, A., & Karni, R. (2017) · Human Genetics · doi:10.1007/s00439-017-1803-x · Cited by 83
Perspective in Alternative Splicing Coupled to Nonsense-Mediated mRNA Decay
García-Moreno, J. F., & Romão, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249424 · Cited by 88
Metadata
- Authors
- Kim, E., Ilagan, J. O., Liang, Y., Daubner, G. M., Lee, S. C.-W., Ramakrishnan, A., Li, Y., Chung, Y. R., Micol, J.-B., Murphy, M. E., Cho, H., Kim, M.-K., Zebari, A. S., Aumann, S., Park, C. Y., Buonamici, S., Smith, P. G., Deeg, H. J., Lobry, C., Aifantis, I., Modis, Y., Allain, F. H.-T., Halene, S., Bradley, R. K., & Abdel-Wahab, O.
- Affiliations
- Fred Hutch Cancer Center (US)
- Yale Cancer Center (US)
- ETH Zurich (CH)
- Memorial Sloan Kettering Cancer Center (US)
- University of Washington (US)
- Yale University (US)
- Université Paris-Sud (FR)
- Howard Hughes Medical Institute (US)
- MRC Laboratory of Molecular Biology (GB)
- Corresponding author
- Bradley, Robert K.
- Abdel-Wahab, Omar
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 27
- Issue
- 5
- Pages
- 617-630
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4429920
- OpenAlex
- W1506037097
- Cited by
- 575
- References
- 34
- Citations by year
- 2026: 42 · 2025: 42 · 2024: 44 · 2023: 55 · 2022: 48 · 2021: 60 · 2020: 59 · 2019: 59 · 2018: 61 · 2017: 43 · 2016: 45 · 2015: 15
- FWCI
- 23.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (acceptedVersion, cc-by-nc-nd)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- Leukemia and Lymphoma Society
- Edward P. Evans Foundation
- Ed Evans Foundation
- National Institutes of Health
- Ellison Medical Foundation (AG-NS-1030-13, R56 DK103854)
- Damon Runyon Cancer Research Foundation (DFS 04-12)
- National Cancer Institute (P30 CA015704, P30 DK056465, T32 CA009657)
- National Institute of General Medical Sciences (101908/Z/13/Z, R01 GM102869)
- National Institute of Diabetes and Digestive and Kidney Diseases (K08 DK082783)
- Wellcome Trust
- U.S. Department of Defense
- Yale Cancer Center
- National Heart, Lung, and Blood Institute (U01 HL099993)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (CRSII3_127454)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- SRSF2, myelodysplastic syndrome, splicing factor mutations, exon recognition, exonic splicing enhancers, aberrant splicing, EZH2, nonsense-mediated mRNA decay, RNA binding, hematopoietic differentiation, hematopoiesis
- MeSH terms
- Serine-Arginine Splicing Factors, Enhancer of Zeste Homolog 2 Protein, Animals, Exons, Mice, Mutant Strains, Mutation, Myelodysplastic Syndromes, Nuclear Proteins, Ribonucleoproteins, RNA Splicing, Gene Expression, Mice, Proteolysis, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
